Please assess the completion status of the following clinical trial:

Trial Title: Initial Safety Evaluation of FibroFix™ Meniscus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject (or guardian, if appropriate) has signed and dated a specific informed consent form~* The subject is over the age of 18~* The subject is able to comply with the protocol-defined preoperative procedures, the postoperative clinical and radiographic evaluations and the recommended rehabilitation regimen as determined by the investigator~* The subject has a diagnosis of an MRI or arthroscopically confirmed irreparable medial meniscus defect~* The meniscal defect should represent 25% or more of the meniscus and be amenable to repair~* The peripheral meniscal rim must be present~* The subject has a functionally intact anterior cruciate ligament~* Haemoglobin \>9g/dL and platelet count \>100,000/mm3 prior to Day 1~* No contraindication to general anaesthetic~* Female subjects of child-bearing potential: a negative urine pregnancy test~Exclusion Criteria:~* The subject has a functionally deficient anterior cruciate ligament~* The subject has concomitant posterior cruciate ligament insufficiency of the involved knee or a concomitant injury that interferes with the subject's ability to comply with the recommended rehabilitation program~* The subject has a diagnosis of untreatable Grade IV Outerbridge Scale degenerative cartilage disease in the involved knee joint~* Patients demonstrating an active local or systemic infection~* Any condition, which in the judgment of the Investigator would preclude adequate evaluation of the FibroFix™ Meniscus scaffold and clinical outcome.~* The subject has a history of confirmed anaphylactoid reaction~* The subject has received local administration of any type of corticosteroid or systemic administration of antineoplastic, immunostimulating, or immunosuppressive agents within 180 days prior to the scheduled surgery~* The subject has evidence of osteonecrosis of the involved knee~* The subject has a medical history that includes a confirmed diagnosis of rheumatoid or inflammatory arthritis, or relapsing polychondritis~* If female and of child-bearing potential: evidence of a positive pregnancy test or a stated intention to become pregnant in the next 6-12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FibroFix™ Meniscus scaffold (Type: EXPERIMENTAL): The test article for this study is the FibroFix™ Meniscus scaffold, which has been developed for repair of defects of the meniscus. It is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.

Based on this trial design, predict the completion outcome and termination type (if applicable).